{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.5","value":"2.34"},{"groupId":"OG001","spread":"95.4","value":"4.10"},{"groupId":"OG002","spread":"0.9","value":"2.17"},{"groupId":"OG003","spread":"6.8","value":"2.32"},{"groupId":"OG004","spread":"4.2","value":"2.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Tmax: Time to maximum measured plasma concentration","dispersionType":"Standard Deviation","groups":[{"description":"E6201 240 mg/m\\^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG000","title":"E6201 240 mg/m^2 Weekly"},{"description":"E6201 320 mg/m\\^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG001","title":"E6201 320 mg/m^2 Weekly"},{"description":"E6201 160 mg/m\\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG002","title":"E6201 160 mg/m^2 Twice Weekly"},{"description":"E6201 240 mg/m\\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG003","title":"E6201 240 mg/m^2 Twice Weekly"},{"description":"E6201 320 mg/m\\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG004","title":"E6201 320 mg/m^2 Twice Weekly"}],"paramType":"MEAN","populationDescription":"All subjects in the FAS who completed at least 1 pharmacokinetic (PK) assessment.","reportingStatus":"POSTED","timeFrame":"Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.","title":"Pharmacokinetics of E6201 in Plasma: Tmax","type":"SECONDARY","unitOfMeasure":"h"}